{"schema_version":"secwatch.filing_event.v1","accession":"0000929638-25-002520","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2025-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.750621+00:00","generated_at":"2026-05-18T09:09:03.101337+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"enGene appoints Astley-Sparke, Grossman, Heffernan to board; promotes three executives","bullets":["Philip Astley-Sparke, William Grossman, Michael Heffernan appointed to Board effective July 8, 2025; Jasper Bos resigned.","Matthew Boyd promoted to Chief Regulatory Officer; Jill Buck to Chief Development Officer; Katherine Chan to Executive Director, Urology Clinical Lead.","New board members have experience in gene therapy, oncology, and product launches; company advancing detalimogene toward planned commercialization.","Board increased from seven to nine members after appointments; no disagreements cited for Bos resignation.","Independent director compensation plan applies; indemnification agreements entered."],"urls":{"canonical":"https://secwatch.observer/filing/0000929638-25-002520","json":"https://secwatch.observer/filing/0000929638-25-002520.json","markdown":"https://secwatch.observer/filing/0000929638-25-002520.md","text":"https://secwatch.observer/filing/0000929638-25-002520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000092963825002520/0000929638-25-002520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000092963825002520/a8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:09:03.101337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}